MedTrace Logo

Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization

NCT00004430 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

I. Demonstrate the safety and efficacy of dihematoporphyrin derivative (DHP) in laser photodynamic therapy (PDT) in patients with corneal neovascularization.

II. Document the histopathologic mechanism of action in selected patients undergoing penetrating keratoplasty following PDT therapy for corneal neovascularization.

III. Facilitate FDA product approval of DHP as a photosensitizing agent for laser treatment in these patients.

IV. Explore the use of this photosensitizer for ocular and cutaneous basal cell and squamous cell carcinoma.

Conditions

  • Corneal Neovascularization

Interventions

DRUG

Dihematoporphyrin derivative

DRUG

prednisolone

PROCEDURE

Laser surgery

Sponsors & Collaborators

  • Eastern Virginia Medical School

    collaborator OTHER

  • Medical College of Hampton Roads

    lead OTHER

Principal Investigators

  • John D. Sheppard · Eastern Virginia Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-09-30
Completion
1998-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004430 on ClinicalTrials.gov